A Phase 4 interventional study of Methylphenidate hydrochloride extended-release capsules in Attention Deficit Hyperactivity Disorder, sponsored by Dar Clinical Research Inc.. Recruiting at 1 site in Canada. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.
Sponsored by Dar Clinical Research Inc. · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 181 studies testing methylphenidate in Attention Deficit Disorder with Hyperactivity — 19 open to participants now, 21 under way, 1 of them phase 3. Methylphenidate · Attention Deficit Disorder with Hyperactivity.
Among the 181 studies testing methylphenidate in Attention Deficit Disorder with Hyperactivity, this one is the 123rd largest by planned enrollment of the 179 interventional ones that give a count, is one of 5 that started in 2026, is one of 87 in phase 4, reaches primary completion later than 12 of the 20 other live ones, and was the 180th registered.
1,821 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 297 are open to participants now.
Browse Attention Deficit Disorder with Hyperactivity studies →19 of the 181 studies testing methylphenidate in Attention Deficit Disorder with Hyperactivity are open now, in 7 countries. Recruiting first, the newest first:
Hugo W. Moser Research Institute at Kennedy Krieger, Inc. · Sites in United States
Ages 6–17
Children's Hospital Medical Center, Cincinnati · Sites in United States
Ages 3–5
St. Jude Children's Research Hospital · Sites in United States
Ages 8–17
NYU Langone Health · Sites in United States
Ages 18–60
VA Office of Research and Development · Sites in United States
Ages 18–65
By country, each count listing its studies:
Methylphenidate: first FDA approval 1955 (RITALIN), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →
Of the 200 Attention Deficit Disorder with Hyperactivity studies recruiting now, 26 (13%) set no upper age limit and 169 (85%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
181 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 20 · Phase 3 47 · Phase 4 87
First in 1986; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 36 is below the median of 72 across 1,439 interventional studies indexed under Attention Deficit Disorder with Hyperactivity.
Median enrollment 68 across the 179 interventional studies. Of the 138 that completed or were terminated, 55 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
49 of 181 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Dar Clinical Research Inc. as lead sponsor.
Dar Clinical Research Inc. has 1 study filed under Attention Deficit Disorder with Hyperactivity — fewer than ten, so there is no comparison to draw.
3 of the studies testing methylphenidate in Attention Deficit Disorder with Hyperactivity that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05776056VA Office of Research and DevelopmentMethylphenidate for the Treatment of PTSD With Associated Neurocognitive Complaints | 2027-03-31 |
| NCT07226219St. Jude Children's Research HospitalMethylphenidate to Address Attention and Executive Deficits Among Children With Sickle Cell Disease | 2027-07-01 |
| NCT07710014Dar Clinical Research Inc.Evaluation of Foquest in Adults 65 Years and Older With ADHD | 2027-07-21 |
Add all 3 to your calendar (.ics) → With an account.
Among the 181 studies testing methylphenidate in Attention Deficit Disorder with Hyperactivity, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is evaluating the safety and effectiveness of Foquest (multilayer-release methylphenidate), a once-daily extended-release medication for attention-deficit/hyperactivity disorder (ADHD), in adults aged 65 years and older.
ADHD can persist into older age and is associated with reduced quality of life and difficulties with executive function. Foquest is currently approved in Canada for the treatment of ADHD in adults up to age 65, but there is very limited research on its use in older adults. People over 65 may respond differently to stimulant medications due to age-related changes in how the body processes drugs, other medical conditions, and increased sensitivity to cardiovascular side effects.
This is an open-label study, meaning all participants will know they are receiving the study medication. There is no placebo group. Participants will take Foquest once daily for approximately 10 weeks, including a 6-week dose adjustment period, a 2-week maintenance period, and a 2-week follow-up period. The dose will start at 25 mg daily and may be increased weekly up to a maximum of 100 mg daily based on how well the participant responds and tolerates the medication.
The main goal of the study is to measure changes in ADHD symptoms using a clinician-rated scale called the Adult ADHD Investigator Symptom Rating Scale (AISRS). The study will also assess changes in executive function, overall clinical improvement, and cardiovascular safety measures including blood pressure, heart rate, and electrocardiograms (ECGs). Safety will be closely monitored throughout the study, with enhanced cardiovascular monitoring during the first 6 weeks of treatment.
This is a prospective, open-label, within-subject (pre-post), investigator-initiated Phase IV trial evaluating the safety and efficacy of Foquest (multilayer-release methylphenidate hydrochloride; MLR-MPH) in adults aged 65 years and older with a DSM-5 diagnosis of ADHD.
Background: Foquest is a once-daily oral stimulant consisting of a 20% immediate-release outer layer and an 80% delayed-release core, with onset of effect within approximately 1 hour and duration of up to 16 hours. It is approved by Health Canada for ADHD in adults up to age 65. The product monograph acknowledges that data are lacking for individuals above this age. Pharmacoepidemiologic evidence (Tadrous et al., 2021) suggests a transient increase in cardiovascular risk during the first 30 days of stimulant initiation in adults aged 66 and older, underscoring the need for careful cardiac screening and monitoring in this population.
Study Design: Each participant will be involved for approximately 10 weeks, comprising a 6-week dose titration phase, a 2-week maintenance phase, and a 2-week follow-up period. Participants will attend 5 in-person visits and 4 phone visits. Foquest will be initiated at 25 mg daily (or an investigator-selected dose based on prior medication history) and titrated weekly to a maximum of 100 mg daily based on efficacy and tolerability.
Cardiovascular Safety Monitoring: Enhanced cardiovascular monitoring is incorporated based on published evidence of early cardiovascular risk with stimulant initiation in older adults. Blood pressure and heart rate are measured in triplicate at screening and assessed at all in-person visits. Twelve-lead ECGs are performed at screening, baseline, Week 3, Week 5, and end of treatment (Week 8). Predefined criteria for treatment interruption include sustained resting heart rate greater than 100 bpm, systolic blood pressure greater than 180 mmHg, or diastolic blood pressure greater than 110 mmHg. Immediate discontinuation criteria include blood pressure at or above 180/120 mmHg, new arrhythmia, or symptoms suggestive of acute cardiovascular or cerebrovascular events.
Primary Endpoint: Mean change from baseline (Week 1) to end of treatment (Week 8) in AISRS total score, analyzed using a paired t-test in the modified intention-to-treat population.
Secondary Endpoints: Change from baseline to Week 8 in ASRS-5 total score, CGI-S score, BRIEF-A Global Executive Composite T-score, and distribution of CGI-I scores at Week 8. Cardiovascular parameters (systolic and diastolic blood pressure, heart rate, QTcF interval) and adverse events will be analyzed as safety endpoints.
Sample Size: 36 participants are planned, allowing for up to 15% attrition to ensure 30 completers, providing 80% power to detect a within-subject effect size of Cohen's d of 0.53 or greater.
This study addresses a critical evidence gap regarding the pharmacological treatment of ADHD in older adults and aims to inform evidence-based prescribing decisions for this underserved population.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All participants receive open-label Foquest (multilayer-release methylphenidate hydrochloride) once daily, initiated at 25 mg and titrated weekly over 6 weeks to an optimal dose up to a maximum of 100 mg daily, followed by a 2-week maintenance phase and a 2-week follow-up period.
Drug: Methylphenidate hydrochloride extended-release capsules
Once-daily oral extended-release methylphenidate capsule with multilayer-release technology (20% immediate-release outer layer, 80% delayed-release core). Starting dose 25 mg daily, titrated weekly over 6 weeks to optimal dose (maximum 100 mg daily) based on efficacy and tolerability. Capsules taken in the morning, swallowed whole or opened and sprinkled on applesauce or yogurt. Available strengths: 25, 35, 45, 55, 70, 85, and 100 mg. Two-week maintenance at optimal dose followed by 2-week follow
Also known as: Foquest, MLR-MPH
Mean Change in Adult ADHD Investigator Symptom Rating Scale (AISRS) Total Score
Mean change from baseline (Week 1) to end of treatment (Week 8) in AISRS total score. The AISRS is an 18-item clinician-administered scale aligned with DSM criteria for ADHD, with each item rated 0-3 (total score range 0-54). Higher scores indicate greater symptom severity. Analysis uses a paired t-test in the modified intention-to-treat population.
Time frame: Baseline (Week 1) to End of Treatment (Week 8)
Mean Change in ASRS-5 Total Score
Mean change from baseline to Week 8 in the Adult ADHD Self-Report Scale version 1.1 (ASRS-5) total score. The ASRS-5 is an 18-item self-report questionnaire with Part A (Inattention) and Part B (Hyperactivity/Impulsivity), items rated 0 (Never) to 4 (Very Often). Analyzed using paired t-test and repeated-measures ANOVA across post-baseline timepoints (Weeks 3, 5, and 8).
Time frame: Baseline (Week 1) to Week 8, with interim assessments at Weeks 3 and 5
Mean Change in Clinical Global Impression - Severity (CGI-S) Score
Mean change from baseline to Week 8 in CGI-S score. The CGI-S is a 7-point clinician-rated scale of overall illness severity (1 = Normal, not at all ill; 7 = Among the most extremely ill patients). A responder analysis will report the proportion of participants achieving CGI-S score of 3 or less (mildly ill or better) at Week 8.
Time frame: Baseline (Week 1) to Week 8
Clinical Global Impression - Improvement (CGI-I) Responder Rate
Distribution of CGI-I scores at Week 8. The CGI-I is a 7-point clinician-rated scale evaluating change from baseline (1 = Very much improved; 7 = Very much worse). The clinical responder rate is defined as the proportion of participants rated as much improved or very much improved (CGI-I score of 2 or less) at Week 8, reported with 95% exact binomial confidence intervals.
Time frame: Week 8 (End of Treatment)
Mean Change in BRIEF-A Global Executive Composite (GEC) T-Score
Mean change from baseline to Week 8 in the Behavior Rating Inventory of Executive Function - Adult Version (BRIEF-A) Global Executive Composite T-score. The BRIEF-A is a 75-item self-report measure of executive functioning in adults aged 18-90, producing norm-referenced T-scores. Higher scores indicate greater executive dysfunction. Individual index scores (Behavioral Regulation Index, Metacognition Index) will also be analyzed.
Time frame: Baseline (Week 1) to Week 8
Change in Systolic Blood Pressure
Mean change from baseline to Week 8 in resting systolic blood pressure (mmHg). Assessed at in-person visits at Weeks 0, 3, 5, and 8. Outlier criteria: systolic BP greater than 140 mmHg or increase greater than 20 mmHg from baseline.
Time frame: Baseline (Week 1) to Week 8, with interim assessments at Weeks 3 and 5
Incidence of Treatment-Emergent Adverse Events
Incidence of treatment-emergent adverse events (TEAEs) summarized by system organ class and preferred term using MedDRA coding. TEAEs tabulated by severity (mild, moderate, severe) and relationship to study medication. Serious adverse events, adverse events leading to dose modification, and adverse events leading to discontinuation reported separately.
Time frame: From first dose of study medication to 14 days after study completion (approximately 10 weeks)
Columbia-Suicide Severity Rating Scale (C-SSRS) Changes
C-SSRS data summarized at each visit using frequency and percentage of participants in each suicidal ideation severity category (0-5), shift tables showing treatment-emergent changes from baseline (new onset or worsening of suicidal ideation category), and incidence of any suicidal behavior events.
Time frame: Baseline (Week 1) through End of Study/Follow-Up (Week 10), assessed at every study visit
Plan to share: Undecided
Started Oct 2026 (actual). Primary completion is estimated for Jul 2027, 9 months after the start.
Of 44 non-industry phase 4 interventional studies under Attention Deficit Disorder with Hyperactivity, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 81. This study's planned 9 months is below that.
Counting every sponsor, half of 62 studies reached it within 38 months; a quarter within 18 and three quarters within 70.
Start moved once since we started tracking on Sep 25, 2026: Jul 2026 → Oct 2026, on Oct 7, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Methylphenidate
Attention Deficit Disorder with Hyperactivity →